Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV) Head to Head Analysis

Roivant Sciences (NASDAQ:ROIV) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Roivant Sciences and Janux Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26 million	2,991.59	-$299.77 million	($0.53)	-64.55
Janux Therapeutics	$10.00 million	113.11	-$113.62 million	($1.64)	-11.28

Janux Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Roivant Sciences and Janux Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Janux Therapeutics	N/A	-11.89%	-11.13%

Volatility and Risk

Roivant Sciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Roivant Sciences and Janux Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1	1	10	1	2.85
Janux Therapeutics	2	2	10	1	2.67

Roivant Sciences presently has a consensus price target of $45.64, indicating a potential upside of 33.40%. Janux Therapeutics has a consensus price target of $36.46, indicating a potential upside of 97.09%. Given Janux Therapeutics’ higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Roivant Sciences.

Summary

Janux Therapeutics beats Roivant Sciences on 9 of the 13 factors compared between the two stocks.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.